Evidence map›Paper›PMID 35608757›Full record

ArticleLa Radiologia medica2022

Role of magnetic resonance imaging following postoperative radiotherapy in clinical decision-making of patients with high-grade glioma.

Francesco Pasqualetti, Giulia Malfatti, Martina Cantarella, Alessandra Gonnelli, Sabrina Montrone, Nicola Montemurro, Giovanni Gadducci, Noemi Giannini, Ilaria Pesaresi, Paolo Perrini and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in La Radiologia medica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Observational
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Francesco PasqualettiRadiation Oncology, Department of Translational Medicine, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy. francep24@hotmail.com.ORCID http://orcid.org/0000-0002-0788-1205
Giulia MalfattiRadiation Oncology, Department of Translational Medicine, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.
Martina CantarellaRadiation Oncology, Department of Translational Medicine, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.
Alessandra GonnelliRadiation Oncology, Department of Translational Medicine, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.
Sabrina MontroneRadiation Oncology, Department of Translational Medicine, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.
Nicola MontemurroDepartment of Neurosurgery, Azienda Ospedaliero Universitaria Pisana (AOUP), Pisa, Italy.
Giovanni GadducciRadiation Oncology, Department of Translational Medicine, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.
Noemi GianniniRadiation Oncology, Department of Translational Medicine, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.
Ilaria PesaresiDepartment of Translational Research and New Surgical and Medical Technologies, University of Pisa, Pisa, Italy.
Paolo PerriniDepartment of Neurosurgery, Azienda Ospedaliero Universitaria Pisana (AOUP), Pisa, Italy.
Riccardo MorgantiDepartmental Section of Statistical Support for Clinical Trials, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
Mirco CosottiniDepartment of Translational Research and New Surgical and Medical Technologies, University of Pisa, Pisa, Italy.
Fabiola PaiarRadiation Oncology, Department of Translational Medicine, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.
Azienda Ospedaliera Universitaria Pisana · ITUniversity of Pisa · ITUniversity of Oxford · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThe present study aims to investigate the role of the first magnetic resonances (MRI) following radio-chemotherapy (RT-CT) in patients diagnosed with high-grade glioma.

methodsWe retrospectively recorded radiological evaluations following RT-CT, symptoms related to disease progression (avoiding any sign due to radiotherapy or chemotherapy) and the change of therapeutic strategy.

resultsIn March 2021, at data analysis, the data of 149 patients diagnosed with high-grade glioma and treated between May 2013 and July 2020 were retrieved for the present analysis. Two out of 122 (1.6%), 5 out of 106 (4.7%) and 8 out of 92 (8.6%) asymptomatic patients received the diagnosis of disease recurrence at the time of the first, second and third MRI, respectively. Otherwise, 16 out of 27 (59.2%), 16 out of 24 (66.6%) and 13 out of 16 (82.2%) symptomatic patients changed their therapy after the first, second and third MRI, respectively. Among patients that experienced radiological signs of distant progression, 10 out of 14 were symptomatic and changed their therapy.

conclusionsMRIs performed by 6 months after the end of RT-CT lead to change treatment strategy mostly in symptomatic patients.

Indexed as

Brain NeoplasmsGliomaClinical Decision-MakingDisease ProgressionHumansMagnetic Resonance ImagingNeoplasm Recurrence, LocalRetrospective StudiesNeuroradiologyPseudoprogressionRadiological assessmentRecurrent glioblastoma

Identifiers

PMID35608757
OpenAlexW4281387926

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.